Literature DB >> 9585065

Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line.

K L Mealey1, R Barhoumi, K Rogers, D T Kochevar.   

Abstract

Canine and human osteosarcoma are very similar with respect to clinical presentation, radiological and histopathological features, metastatic rate and pattern and response to therapy. For these reasons, canine osteosarcoma is a useful intermediate model for the disease in humans. Overexpression of P-glycoprotein, the product of the MDR1 gene, is the most important predictor of an adverse clinical course in human patients with osteosarcoma. Exposure of canine osteosarcoma cells to doxorubicin resulted in overexpression of MDR1 mRNA and P-glycoprotein. Furthermore, these cells failed to accumulate doxorubicin intracellularly and were less sensitive to vincristine-induced cytotoxicity as compared to parental cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585065     DOI: 10.1016/s0304-3835(98)00004-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors.

Authors:  C M Cannon; J Pozniak; M C Scott; D Ito; B H Gorden; A J Graef; J F Modiano
Journal:  Vet Comp Oncol       Date:  2013-02-15       Impact factor: 2.613

2.  In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors.

Authors:  Kenneth M Rassnick; Josephia R Muindi; Candace S Johnson; Cheryl E Balkman; Nithya Ramnath; Wei-Dong Yu; Kristie L Engler; Rodney L Page; Donald L Trump
Journal:  Cancer Chemother Pharmacol       Date:  2008-02-02       Impact factor: 3.333

3.  Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas.

Authors:  Victor Hugo Villar; Oliver Vögler; Jordi Martínez-Serra; Rafael Ramos; Silvia Calabuig-Fariñas; Antonio Gutiérrez; Francisca Barceló; Javier Martín-Broto; Regina Alemany
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

4.  Celecoxib Prevents Doxorubicin-Induced Multidrug Resistance in Canine and Mouse Lymphoma Cell Lines.

Authors:  Edina Karai; Kornélia Szebényi; Tímea Windt; Sára Fehér; Eszter Szendi; Valéria Dékay; Péter Vajdovich; Gergely Szakács; András Füredi
Journal:  Cancers (Basel)       Date:  2020-04-29       Impact factor: 6.639

5.  Enhanced Cytotoxic Effect of Doxorubicin Conjugated to Glutathione-Stabilized Gold Nanoparticles in Canine Osteosarcoma-In Vitro Studies.

Authors:  Anna Małek; Bartłomiej Taciak; Katarzyna Sobczak; Agnieszka Grzelak; Michał Wójcik; Józef Mieczkowski; Roman Lechowski; Katarzyna A Zabielska-Koczywąs
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

6.  P-glycoprotein is expressed and causes resistance to chemotherapy in EBV-positive T-cell lymphoproliferative diseases.

Authors:  Mayumi Yoshimori; Honami Takada; Ken-Ichi Imadome; Morito Kurata; Kouhei Yamamoto; Takatoshi Koyama; Norio Shimizu; Shigeyoshi Fujiwara; Osamu Miura; Ayako Arai
Journal:  Cancer Med       Date:  2015-07-08       Impact factor: 4.452

7.  Poly(ethylene glycol)-sheddable reduction-sensitive polyurethane micelles for triggered intracellular drug delivery for osteosarcoma treatment.

Authors:  Zhengjie Yang; Qianping Guo; Yan Cai; Xuesong Zhu; Caihong Zhu; Yuling Li; Bin Li
Journal:  J Orthop Translat       Date:  2019-12-06       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.